[
    "A protects against asthma through an IL-10-dependent mechanism.J Clin Invest 2013\uff1b123(3):pp1216-28.</p>8.Kormann MS,Hasenpusch G,Aneja MK,Nica G,Flemmer AW,Herber-Jonat S,Huppmann M,Mays LE,Illenyi M,Schams A,Griese M,Bittmann I,Handgretinger R,Hartl D,Rosenecker J,and Rudolph C:Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.Nat Biotechnol 2011\uff1b29(2):pp154-7.</p>9.Chow MY and Lam JK:Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation.Curr Pharm Des 2015\uff1b21(27):pp3854-66.</p>10.Mitchell J and Nagel M:Particle size analysis of aerosols from medicinal inhalers.KONA Powder and Particle Journal 2004\uff1b22:pp32-65.</p>11.Malcolmson RJ and Embleton JK:Dry powder formulations for pulmonary delivery.Pharmaceutical science&amp;technology today 1998\uff1b1(9):pp394-398.</p>12.Chan HK:Dry powder aerosol delivery systems:current and future research directions.J Aerosol Med 2006\uff1b19(1):pp21-7.</p>13.Tavernier G,Andries O,Demeester J,Sanders NN,De Smedt SC,and Rejman J:mRNA as gene therapeutic:how to control protein expression.J Control Release 2011\uff1b150(3):pp238-47.</p>14.Johler SM,Rejman J,Guan S,and Rosenecker J:Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration.PLoS One 2015\uff1b10(9):ppe0137504.</p>15.Patel AK,Kaczmarek JC,Bose S,Kauffman KJ,Mir F,Heartlein MW,DeRosa F,Langer R,and Anderson DG:Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium.Adv Mater 2019\uff1b31(8):ppe1805116.</p>16.Robinson E,MacDonald KD,Slaughter K,McKinney M,Patel S,Sun C,and Sahay G:Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis.Mol Ther 2018\uff1b26(8):pp2034-2046.</p>17.Qiu Y,Chow MYT,Liang W,Chung WWY,Mak JCW,and Lam JKW:From Pulmonary Surfactant,Synthetic KL4 Peptide as Effective siRNA Delivery Vector for Pulmonary Delivery.Mol Pharm 2017\uff1b14(12):pp4606-4617.</p>18.Kinbara K:Monodisperse engineered PEGs for bio-related applications.Polymer Journal 2018\uff1b50(8):pp689.</p>19.Chow MYT,Qiu Y,Lo FFK,Lin HHS,Chan HK,Kwok PCL,and Lam JKW:Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer.Int J Pharm 2017\uff1b530(1-2):pp40-52.</p>20.Liang W,Chow MYT,Chow SF,Chan HK,Kwok PCL,and Lam JKW:Using two-fluid nozzle for spray freeze drying to produce porous powder formulation of naked siRNA for inhalation.Int J Pharm 2018\uff1b552(1-2):pp67-75.</p>21.The British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare Products Regulatory Agency,The British Pharmacopoeia 2016.2016,The Stationery Office.</p>22.Liao Q,Yip L,Chow MYT,Chow SF,Chan HK,Kwok PCL,and Lam JKW:Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition.Int J Pharm 2019\uff1b560:pp144-154.</p>23.Guan S and Rosenecker J:Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.Gene therapy 2017\uff1b24(3):pp133.</p>24.Ito T,Okuda T,"
]